Quanterix Corporation (NASDAQ: QTRX) recently announced that it has received a notice from the NASDAQ Stock Market LLC, stating that it is not in compliance with NASDAQ listing rule 5250(c)(1) due to its delay in filing the quarterly report on Form 10-Q for the quarter ended September 30, 2024. The company has until January 20, 2025, to submit a plan to regain compliance with the rule.
The delay in filing the Form 10-Q is due to the need to restate the company’s audited consolidated financial statements as of December 31, 2023, and 2022, as well as its unaudited consolidated financial statements for various quarterly periods in 2022, 2023, and 2024.
Quanterix is working diligently to complete the filing of the Form 10-Q and remains on track to complete the restatement and all required filings by the end of 2024.
The company's ultrasensitive biomarker detection technology, Simoa®, has been instrumental in earlier biomarker detection in blood, serum, or plasma. Quanterix's precision instruments, digital immunoassay technology, and CLIA-certified accelerator laboratory have supported research in neurology, oncology, immunology, cardiology, and infectious disease, with research published in more than 3,100 peer-reviewed journals.
Quanterix's dedication to completing its filings and its innovative technology underscores its commitment to advancing disease understanding and management in various medical fields. As a result of these announcements, the company's shares have moved 0.3% on the market, and are now trading at a price of $11.75. For more information, read the company's full 8-K submission here.
